Yunnan Baiyao Group (000538) H1 2024 earnings summary

Executive summary

• Operating revenue for 1H 2024 reached RMB 20.46 billion, up 0.72% year-over-year, with net profit attributable to shareholders at RMB 3.19 billion, a 12.76% increase, setting a new historical high for the period.

• Industrial revenue accounted for 37.41% of total revenue, up 0.49 percentage points, and industrial gross profit margin rose 3.10 percentage points to 67.37% year-over-year.

• Net cash flow from operating activities increased 44.84% year-over-year to RMB 3.26 billion, and management expenses decreased by 4.95%.

• The company completed a share repurchase cancellation, reducing share capital by 12.6 million shares, and distributed a cash dividend of RMB 3.71 billion, representing 90.53% of 2023 net profit.

Financial highlights

• Net profit attributable to shareholders: RMB 3.19 billion, up 12.76% year-over-year.

• Operating revenue: RMB 20.46 billion, up 0.72% year-over-year.

• Net cash flows from operating activities: RMB 3.26 billion, up 44.84% year-over-year.

• Basic and diluted EPS: RMB 1.79, up 13.29% year-over-year.

• Weighted average ROE: 7.93%, up 0.76 percentage points.

• Total assets: RMB 54.37 billion, up 1.08% from year-end 2023.

Outlook and guidance

• Strategic focus on becoming a leading Chinese and world-class modern pharmaceutical group, with emphasis on high-quality growth, efficiency, and product structure optimization.

• Continued investment in R&D, digital transformation, and internationalization, with a dual approach of internal growth and external expansion.

• Plans to further develop TCM resources, pain management, and health products, and to enhance digital and intelligent management across the value chain.